Under the aegis of the Department of Clinical Immunology of SGPGI-MS, he undertook several projects of the Indian Council of Medical Research which included a study of the genetic effects in the wake of the Bhopal Gas Tragedy of December 1984 and a study of Handigodu syndrome prevalent in some parts of Karnataka which he identified as autosomal-dominant spondylo-epiphyseal dysplasia. He also undertook a task for Central Drug Research Institute (CDRI) when the institute developed "Guggulipid", a hypolipideamic agent produced from the Ayurvedic drug, guggul. He completed the clinical trials for the phytopharmaceutical preparation which was subsequently cleared by the Drug Controller General of India for commercial marketing.